Comparative Pharmacology
Head-to-head clinical analysis: RASUVO versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RASUVO versus SIKLOS.
RASUVO vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
Subcutaneous injection: 200 mg once weekly.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category C
Category C
Antimetabolite
Antimetabolite